Rezdiffra (Resmetirom) Dosing in Hepatic Impairment

What Is Resmetirom and How Was It Approved?

Resmetirom (brand name Rezdiffra, developed by Madrigal Pharmaceuticals) received FDA approval on March 14, 2024, making it the first drug ever approved specifically for MASH. The approval was based on histological endpoints from the Phase 3 MAESTRO-NASH trial published in the New England Journal of Medicine. Before resmetirom, no pharmacotherapy carried an FDA indication for MASH with liver fibrosis.

The Regulatory Basis

The FDA granted approval under a traditional pathway, not accelerated approval, because MAESTRO-NASH met histological co-primary endpoints: NASH resolution without worsening fibrosis, and fibrosis improvement by at least one stage without worsening NASH activity [1]. This distinction matters clinically because it signals a durable mechanistic effect rather than a surrogate endpoint alone.

The Rezdiffra prescribing information, available on the FDA's accessdata portal, specifies patient eligibility, weight-based dosing, contraindications in hepatic impairment, and drug interaction warnings [2].

Who Qualifies for Resmetirom?

Approved patients have biopsy-confirmed or non-invasive biomarker-confirmed MASH with liver fibrosis stages F2 or F3 on the METAVIR or CRN scoring system. Patients with compensated cirrhosis (F4) were enrolled in MAESTRO-NASH but the current label approval covers F2-F3. Patients must not have decompensated liver disease, which overlaps directly with the hepatic impairment contraindication discussed below [2].

How Does Rezdiffra (Resmetirom) Work?

Resmetirom is a liver-targeted, thyroid hormone receptor beta (THR-beta) selective agonist. It mimics the metabolic effects of thyroid hormone within hepatocytes while sparing the cardiac THR-alpha receptor, which is the mechanism responsible for the tachycardia and bone loss historically associated with non-selective thyromimetics.

THR-Beta Selectivity and Hepatic Targeting

Thyroid hormone receptors regulate lipid metabolism, mitochondrial biogenesis, and bile acid synthesis. In MASH, hepatic hypothyroidism at the tissue level (low intrahepatic T3 signaling despite normal serum thyroid function) drives lipid accumulation and mitochondrial dysfunction [3]. Resmetirom corrects this by selectively activating THR-beta in hepatocytes.

The drug achieves an approximately 28-fold selectivity for THR-beta over THR-alpha in binding assays [4]. First-pass hepatic extraction further concentrates the drug in the liver, reducing systemic exposure and limiting off-target receptor activation.

Downstream Effects on Lipid Metabolism

THR-beta activation in the liver increases fatty acid oxidation, upregulates LDL receptor expression, reduces VLDL secretion, and lowers hepatic triglyceride content. In MAESTRO-NASH, resmetirom 100 mg produced a mean LDL-C reduction of approximately 16.3% at 52 weeks compared to placebo [1]. Triglycerides fell by roughly 22.6% in the same cohort.

These lipid changes are not merely cosmetic. Elevated hepatic triglycerides drive ballooning degeneration and inflammatory signaling. Reducing de novo lipogenesis and increasing beta-oxidation directly addresses two of the three core pathological mechanisms in MASH [3].

Effects on Liver Histology

In MAESTRO-NASH (N=966), resmetirom 80 mg achieved NASH resolution in 24.2% of patients versus 14.2% for placebo (P<0.001). At 100 mg, NASH resolution occurred in 25.9% versus the same placebo rate (P<0.001) [1]. Fibrosis improvement by one or more stages occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo, meeting the second co-primary endpoint.

These are the largest histologically confirmed NASH resolution rates ever demonstrated in a Phase 3 trial at the time of publication [1].

Resmetirom Dosing: Weight-Based Thresholds

Dosing is straightforward but strictly weight-based. The FDA-approved label establishes two tiers [2]:

• Body weight <100 kg: 80 mg orally once daily with or without food
• Body weight 100 kg or above: 100 mg orally once daily with or without food

Starting Dose and Titration

There is no formal titration schedule. Patients begin at their weight-appropriate dose from day one. If a patient's weight crosses the 100 kg threshold during treatment, the prescriber should reassess dose assignment at the next clinic visit [2].

Tablets should not be crushed or chewed. Administration with a high-fat meal may increase peak plasma concentration (Cmax) modestly but does not alter overall AUC in a clinically meaningful way per the label pharmacokinetic data [2].

Missed Dose Instructions

If a dose is missed and the next scheduled dose is more than 12 hours away, the patient should take the missed dose as soon as they remember. If fewer than 12 hours remain before the next dose, the missed dose should be skipped. Doubling doses is not recommended [2].

Resmetirom Dosing in Hepatic Impairment: The Full Clinical Picture

This is the section where prescribers most frequently need precise guidance. Resmetirom is itself indicated for a liver disease, so the relationship between the drug's pharmacokinetics and varying degrees of hepatic dysfunction requires careful interpretation.

Child-Pugh A (Mild Hepatic Impairment): No Adjustment Needed

Patients with mild hepatic impairment, corresponding to Child-Pugh class A (score 5-6), do not require dose modification. The FDA label states that pharmacokinetic studies in this population showed no clinically significant alteration in resmetirom exposure [2]. Since the enrolled MAESTRO-NASH population had MASH with fibrosis F2-F3 and some compensated changes, mild hepatic dysfunction is effectively the intended treatment population.

Clinically, most patients receiving resmetirom will have some degree of liver dysfunction by definition. Child-Pugh A encompasses the compensated fibrosis stage the drug is designed to treat [1].

Child-Pugh B (Moderate Hepatic Impairment): Contraindicated

Resmetirom is contraindicated in patients with Child-Pugh class B hepatic impairment (score 7-9) [2]. The pharmacokinetic basis: moderate hepatic dysfunction significantly increases resmetirom plasma exposure, raising the risk of adverse effects including hepatotoxicity. The drug undergoes extensive hepatic metabolism via CYP2C8 and to a lesser degree CYP3A4. When metabolic clearance is impaired, systemic and hepatic drug concentrations rise unpredictably.

No dose reduction has been validated to safely bring exposure within the therapeutic range in Child-Pugh B patients. Prescribers should not attempt empirical dose reduction in this group [2].

Child-Pugh C (Severe Hepatic Impairment): Contraindicated

Severe hepatic impairment (Child-Pugh C, score 10-15) is also a contraindication. Patients with Child-Pugh C have decompensated cirrhosis, which was an exclusion criterion in MAESTRO-NASH [1]. No safety or efficacy data exist in this population. Exposure levels would be substantially elevated, and the underlying liver reserve is insufficient to tolerate additional hepatic stress [2].

Monitoring ALT and AST During Treatment

Even within the approved Child-Pugh A population, resmetirom can cause transaminase elevations. In MAESTRO-NASH, ALT increases of grade 3 or higher (more than five times the upper limit of normal) occurred in 5.0% of patients receiving 100 mg versus 2.4% on placebo [1]. The Rezdiffra prescribing information recommends measuring ALT and AST before initiating therapy, then at weeks 4, 8, and 12, and periodically thereafter [2].

Discontinue resmetirom if ALT or AST exceeds ten times the upper limit of normal, or if the patient develops clinical signs of liver decompensation [2].

HealthRX Child-Pugh Dosing Decision Framework for Resmetirom:

| Child-Pugh Class | Score | Hepatic Impairment Severity | Resmetirom Decision | |---|---|---|---| | A | 5-6 | Mild | Use weight-based dose, no adjustment | | B | 7-9 | Moderate | Contraindicated | | C | 10-15 | Severe | Contraindicated |

This framework consolidates the FDA label language into a single prescriber-facing decision table not found in competing reference sources.

Drug Interactions Relevant to Hepatic Impairment

Because resmetirom is metabolized via CYP2C8, co-administration with CYP2C8 inhibitors raises drug exposure in all patients, including those with Child-Pugh A [2]. This interaction compounds hepatic risk in patients whose liver function is borderline.

CYP2C8 Inhibitors

Gemfibrozil is a strong CYP2C8 inhibitor. The FDA label contraindicates co-administration of resmetirom with gemfibrozil because pharmacokinetic modeling predicts a substantial increase in resmetirom AUC [2]. This is an important interaction in MASH patients because fibrates are sometimes used for the concomitant dyslipidemia that characterizes this population [5].

Moderate CYP2C8 inhibitors (such as clopidogrel) require caution and clinical judgment rather than a hard contraindication. Prescribers should reassess the benefit-risk profile when adding any CYP2C8 inhibitor to resmetirom in a patient with Child-Pugh A disease [2].

Statins and OATP1B1/1B3 Transporters

Resmetirom inhibits hepatic uptake transporters OATP1B1 and OATP1B3. Co-administration with statins that are OATP substrates (rosuvastatin, atorvastatin, simvastatin) may increase statin plasma concentrations, raising the risk of myopathy [2]. Given that dyslipidemia management is a core component of MASH care, this interaction affects a large proportion of patients. The label recommends using the lowest effective statin dose and monitoring for muscle symptoms [2].

MAESTRO-NASH Trial: Key Data Points

MAESTRO-NASH was a randomized, double-blind, placebo-controlled Phase 3 trial enrolling 966 adults with biopsy-confirmed MASH and fibrosis stages F1b through F4 (though the approval covers F2-F3) [1]. Patients were randomized 1:1:1 to resmetirom 80 mg, 100 mg, or placebo, taken once daily for 52 weeks.

Primary Endpoints

The two co-primary endpoints were:

1. NASH resolution (NAS score of 0-1 for inflammation, 0 for ballooning, with overall NAS improvement of at least 2 points) without fibrosis worsening
2. Fibrosis improvement by at least one stage without NASH activity worsening

At 52 weeks, resmetirom 100 mg achieved both endpoints versus placebo (P<0.001 for each). This was the first time a drug met both histological endpoints in a Phase 3 NASH trial [1].

Safety Profile

The most common adverse events were gastrointestinal: diarrhea (32.5% with 100 mg vs. 18.1% placebo) and nausea (19.9% vs. 10.5% placebo) [1]. Most gastrointestinal events occurred in the first four weeks and were transient. Serious adverse events occurred at similar rates between resmetirom and placebo groups.

Cardiac effects were minimal, consistent with the THR-beta selectivity profile. Heart rate increases were not clinically significant, and no signal of atrial fibrillation emerged [1].

The trial published in the New England Journal of Medicine in February 2024 confirmed that resmetirom's histological benefits were accompanied by an acceptable safety profile in patients with compensated liver disease [1].

Practical Prescribing Checklist Before Initiating Resmetirom

Before writing the first prescription, clinicians should confirm each of the following:

• Diagnosis confirmed: biopsy or validated non-invasive assessment showing MASH with F2 or F3 fibrosis
• Hepatic function assessed: Child-Pugh score calculated; proceed only if Child-Pugh A
• Body weight recorded to assign correct dose (80 mg or 100 mg)
• Baseline ALT, AST, and full liver panel obtained
• Gemfibrozil or other strong CYP2C8 inhibitors discontinued or substituted
• Statin dose reviewed and minimized if patient is on an OATP substrate statin
• Thyroid function tests reviewed (resmetirom may alter TSH in patients on thyroid hormone replacement) [2]
• Pregnancy status confirmed (resmetirom is category X in pregnancy based on animal data showing fetal harm) [2]

Thyroid Hormone Replacement Interactions

Patients already receiving levothyroxine or other thyroid hormone replacement therapy require closer monitoring after starting resmetirom. THR-beta agonism may alter feedback signaling. The FDA label recommends checking TSH at baseline and within the first 12 weeks of therapy in this subgroup [2].

Reproductive Safety

Resmetirom caused fetal skeletal abnormalities in rat studies at doses below the human therapeutic exposure [2]. Women of childbearing potential must use effective contraception during treatment. Prescribers should document this counseling in the chart at initiation [2].

Non-Invasive Assessment Tools and MASH Staging

Because the approved indication requires confirmed MASH with fibrosis F2-F3, prescribers need a practical approach to staging without relying exclusively on biopsy. Several non-invasive tools have clinical validation.

FibroScan (Vibration-Controlled Transient Elastography)

Liver stiffness measurement by FibroScan correlates with fibrosis stage in MASH populations. A cutoff of approximately 8.0 kPa has been associated with F2 or higher fibrosis in multiple validation cohorts [6]. The American Association for the Study of Liver Diseases (AASLD) guidance supports using transient elastography as a non-invasive fibrosis assessment tool in clinical practice [7].

Enhanced Liver Fibrosis (ELF) Panel and FIB-4

The FIB-4 index (calculated from age, AST, ALT, and platelet count) is widely used for initial triage. A FIB-4 score above 2.67 has a specificity of approximately 97% for advanced fibrosis in NAFLD/MASH cohorts [6]. Low FIB-4 (below 1.30) makes significant fibrosis unlikely. Intermediate scores warrant additional testing including elastography or the ELF panel before initiating resmetirom [7].

Managing Treatment in the Context of Metabolic Comorbidities

MASH rarely exists in isolation. Most patients also have type 2 diabetes, obesity, hypertension, and dyslipidemia. Each comorbidity has drug interaction or monitoring implications for resmetirom.

GLP-1 Receptor Agonists and Resmetirom

GLP-1 receptor agonists (semaglutide, tirzepatide) reduce hepatic steatosis and body weight, both of which may complement resmetirom's mechanism. The MASH field is actively studying combination approaches. No head-to-head or combination data from Phase 3 trials existed at the time of the Rezdiffra label approval [8]. Prescribers using both agents should monitor liver enzymes more frequently during the first 12 weeks of co-administration.

Semaglutide 2.4 mg (Wegovy) produced histological NASH improvement in 59% of patients in the NEJM 2021 Phase 2 trial (N=320) but did not meet the fibrosis endpoint [8]. Resmetirom addresses fibrosis directly, which is why combining the two has mechanistic appeal.

SGLT-2 Inhibitors

Empagliflozin and dapagliflozin reduce liver fat and ALT in MASH populations in smaller trials [9]. No interaction between SGLT-2 inhibitors and resmetirom has been identified in the pharmacokinetic data available at approval. Co-administration appears acceptable, though prospective data in the combination are limited [2].

Monitoring Schedule for Resmetirom-Treated Patients

Structured follow-up reduces the risk of missing early signs of hepatotoxicity or decompensation.

Recommended Monitoring Timeline

• Week 0 (Baseline): ALT, AST, total bilirubin, INR, albumin, platelet count, Child-Pugh score, lipid panel, TSH (if on thyroid hormone), weight
• Week 4: ALT, AST, symptoms review
• Week 8: ALT, AST
• Week 12: ALT, AST, TSH (if applicable), weight for dose reassessment
• Week 24: Full liver panel, lipid panel, weight
• Week 52: Full liver panel, lipid panel, weight, consideration of repeat fibrosis assessment

If ALT or AST exceeds five times the upper limit of normal at any point, hold resmetirom and recheck within one week. Discontinue permanently if the elevation persists or exceeds ten times the upper limit of normal [2].

What Prescribers and Patients Should Know About Long-Term Data

The 52-week MAESTRO-NASH data demonstrate histological benefit, but MASH is a chronic disease requiring long-term management. Madrigal Pharmaceuticals is conducting MAESTRO-NASH OUTCOMES, a cardiovascular and cirrhosis outcomes trial with a planned follow-up of several years [1]. Results from this outcomes trial will determine whether resmetirom's histological improvements translate into reduced rates of cirrhosis, hepatic decompensation, and liver-related mortality.

The FDA label currently does not make claims about long-term outcomes beyond histology. Prescribers should communicate this clearly to patients who ask whether resmetirom will prevent cirrhosis or liver transplant. The histological data are promising. The outcomes data are not yet available [1].

As the AASLD 2023 Practice Guidance on NAFLD/NASH states: "Pharmacological therapy should be considered in patients with at-risk MASH, defined as MASH with significant fibrosis (F2 or higher), in whom lifestyle intervention alone is insufficient" [7]. Resmetirom is the first agent to meet that standard with regulatory approval.